{
    "clinical_study": {
        "@rank": "62054", 
        "arm_group": [
            {
                "arm_group_label": "Pregnant women", 
                "description": "Women during first trimester of pregnancy (age: 18-45)\nGroup contain 50 healthy pregnant  women, age 18-45. Sera will be taken from: 1. the same branula that will be introduced into the pregnant women as a routine during pregnancy termination procedure.2. from the vein of volunteered pregnant women which do not terminate pregnancy. First trimester placenta will be collected after pregnancy termination.\nThe measure of outcome is composite and includes several changes:\nChanges in:\ncell death (% from tested cells)\ncell cycle (% cells in G1, G2 and S phases)\ncell migration (% closure in Scratch test)\ncell invasion (% cells passing through membrane in Transwell assay)\nRNA repertoire (Fold change)\nmiRNA repertoire (Fold change) Investigators will not treat the women with any drug."
            }, 
            {
                "arm_group_label": "Non pregnant women", 
                "description": "Group contain 50 healthy women, age 18-45. Sera will be taken from the vein of the volunteered  women. Investigators will not treat the women with any drug."
            }
        ], 
        "biospec_descr": {
            "textblock": "Placentae will be collected and used in cell culture experiments for a week. Their proteins\n      and RNA will be analyzed."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Maternal malignancy during pregnancy is estimated to occur in 1 out of 1000 pregnancies.\n      Controversy exists regarding the effect of pregnancy on cancer prognosis. Gestational\n      hormones and pregnancy-related growth factors may induce a more aggressive behavior in\n      malignant cells. However, metastasis to the products of conception is rare. In the current\n      study investigators wish to analyze the effect of placental explants on cancer cells\n      (cervical, ovarian, thyroid, melanoma, lymphoma, leukemia and  breast)phenotype (cell death,\n      proliferation, migration , invasion), signaling pathway, mRNA, miRNA and protein expression."
        }, 
        "brief_title": "The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "detailed_description": {
            "textblock": "In the Oncogenetic laboratory cancer cells will be exposed to first trimester human\n      placental explants or to serum collected from pregnant women. As a control cancer cells will\n      be cultured alone or in the presence of sera collected from young (18-45) non pregnant\n      women.\n\n      Placentae, 6-9 weeks gestational age, will be retrieved from terminated normal pregnancies.\n      The placenta will be taken after pregnancy termination, thus, no harm will be caused for the\n      women.\n\n      The sera will be collected from the women by an authorized physician. It will be taken from:\n      1. the vein of the non pregnant women and volunteered pregnant women. 2. from the same\n      branula that will be introduced into the pregnant women as a routine during pregnancy\n      termination procedure.\n\n      Following culture investigators will analyze the cancer cells phenotype (cell death,\n      proliferation, migration, and invasion), signaling pathway, mRNA, miRNA and protein\n      expression.\n\n      Sera will be collected from 50 pregnant women and 50 non pregnant women. Placentae will be\n      collected from 50 pregnant women."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy women\n\n          -  Age 18-45.\n\n          -  Pregnant (6-9 weeks) and non pregnant women.\n\n        Exclusion Criteria:\n\n        \u2022 Placentae that were destroyed during pregnancy termination."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Healthy women Age 18-45. Pregnant (6-9 weeks) and non pregnant women."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879436", 
            "org_study_id": "0053-13-MMC"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pregnancy, Placenta, Cancer", 
        "lastchanged_date": "June 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kfar-Saba", 
                    "country": "Israel"
                }, 
                "name": "Oncogenetic Laboratory, Meir Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Michael Lishner, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Shelly Tartakover Matalon, Ph.D", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells", 
        "overall_contact": {
            "email": "michael2@clalit.org.il", 
            "last_name": "Michael Lishner, MD", 
            "phone": "97297472534"
        }, 
        "overall_contact_backup": {
            "email": "matalon.shelly@clalit.org.il", 
            "last_name": "Shelly Tartakover Matalon, Ph.D", 
            "phone": "97297472841"
        }, 
        "overall_official": {
            "affiliation": "Meor Medical Center, Kfar-Saba, Israel", 
            "last_name": "Michael Lishner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The measure of outcome is composite and includes several changes:\nChanges in:\ncell death (% from tested cells)\ncell cycle (% cells in G1, G2 and S phases)\ncell migration (% closure in Scratch test)\ncell invasion (% cells passing through membrane in Transwell assay)\nRNA repertoire (Fold change)\nmiRNA repertoire (Fold change)", 
            "measure": "Cancer cell phenotype (in the laboratory)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 24 hours and 72 hours"
        }, 
        "reference": {
            "PMID": "20719812", 
            "citation": "Tartakover-Matalon S, Mizrahi A, Epstein G, Shneifi A, Drucker L, Pomeranz M, Fishman A, Radnay J, Lishner M. Breast cancer characteristics are modified by first trimester human placenta: in vitro co-culture study. Hum Reprod. 2010 Oct;25(10):2441-54. doi: 10.1093/humrep/deq227. Epub 2010 Aug 18."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879436"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Meir Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meir Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}